Abstract:
PROBLEM TO BE SOLVED: To obtain a cephalosporin derivative useful as an intermediate for pharmaceutically useful cephalosporin in an advantageous process by treating a specific phosphonium salt with a base in toluene and then reacting in the same way with a solution containing a specific aldehyde at a specific temperature and setting the mole ratio of the above reactants in a specific range. SOLUTION: The objective compound of formula IV is obtained by treating a phosphonium salt of formula I (R is H, a lower alkyl or the like substitutable with one or more groups such as carboxy or the like; Ph is phenyl) [e.g. (R, S) (1-cyclopropylmethyl-2-oxo-pyrrolidin-3-yl)-triphenyl-bromophosphonium or the like] with a base in toluene changing into an ylide of formula II and then reacting in the same way a solution containing an aldehyde of formula III (R1 is an amino protecting group; R2 is a carboxy protecting group) in a polar solvent at about -80 to 0 deg.C, and in this case the compound of formula I, the above-mentioned base and the compound of formula III are used in the molar ratio of 1.15:1.1:1.0 to 1.3:1.25:1.0.
Abstract:
PROBLEM TO BE SOLVED: To easily obtain in high yield the subject compound useful as a pharmaceutically active substance or intermediate for producing agrochemicals by converting a specific compound to a pyrrolidine derivative in the presence of a specific primary amine followed by reaction of the pyrrolidine derivative under pressure, optionally in a solvent, in the presence of a specific amine. SOLUTION: This compound of formula III or IV (e.g. allyl 3- aminopyrrolidine-1-carboxylate) is obtained by converting a compound of formula I (X is a protected OH) (e.g. methanesulfonic acid 3,4-bis- methanesulfonyloxybutyl ester) to a pyrrolidine derivative of formula II in the presence of a primary amine of the formula R1NH2 (R1 is H, an alkyl or the like)(e.g. benzylamine) followed by reaction of the pyrrolidine derivative pref. under a pressure of 50-80 bar, optionally in a solvent, in the presence of a compound of the formula R2R3NH (R2 and R3 are each H, an alkyl or the like)(e.g. ammonia) pref. at 20-200 deg.C.
Abstract:
PROBLEM TO BE SOLVED: To obtain a (11Z, 13Z)-7,10-dihydro-10-hyroxyretiny acylate which is useful for production of vitamin A acylate under conditions of easy catalyst separation and high yield by acrylating a specific hydroxyretional compound in the presence of an enzymatic catalyst lipase under specific conditions of the acylation. SOLUTION: This (11Z, 13Z)-7,10-dihydro-10-hyroxyretiny acylate of formula II (R is a 1-23C alkyl or 2-23C alkyl having 1-3 double bonds) is obtained by selectively monoacylating a (11Z, 13Z)-7,10-dihydro-10-hyroxyretinol of formula I with a lipase which is present in a suspension [for example, a suspension of (granulated) diatomaceous earth on which lipase has been fixed, or a suspension of macroporous polyacrylate on which lipase from Candida antarctica has been fixed]. This selective acylation can efficiently prevent formation of undesirable by-products, such as (11Z, 13Z)-7,10-dihydro-10-acetoxyretinyl acetate.
Abstract:
PROBLEM TO BE SOLVED: To obtain the subject pyridine at a more yield in a smaller number of reaction processes by reacting a specific monoene compound with an acrylic compound, and further reacting with a hydrogen halide. SOLUTION: This objective pyridine expressed by formula III (e.g. 2-chloro-5- isopropylpyridine) is obtained by (A) reacting a compound of the formula: R -CH=CH-R R is a lower alkyl; R is a di(lower alkyl) amino, a 5-membered or 6-membered N-heterocyclic group having a free valence bond on an N-atom} preferably 1-(N-morpholino)prop-1-ene} with an acrylic compound of formula I (X is a halogen) preferably in an anhydrous solvent such as a hydrocarbon halide and in the presence of an acid anhydride, and (B) reacting the resultant compound of formula II with a hydrogen halide (preferably gaseous HBr or HCl, in situ) under an anhydrous condition.
Abstract:
New process for the preparation of 4-alkoxytetrahydropyrane derivatives used in the preparation of 4-alkoxy-7-(tetrahydropyran-4-yl)-benzothiazol-2-ylamine and derivatives.
Abstract:
The present invention relates to a process for preparation of amino substituted benzothiazole derivatives of formula (I), wherein R , R and R are independently from each other hydrogen, lower alkyl, lower alkoxy or halogen; R is hydrogen, lower alkyl, lower alkyloxy, halogen, or is a five or six membered non aromatic heterocyclyl group, unsubstituted or substituted by lower alkyl or an oxo-group, or is -NR R wherein R and R are independently from each other hydrogen, lower alkyl, -C(O)-lower alkyl, -(CH2)nO-lower alkyl or benzyl, opionally substituted by lower alkyl, or is an five or six membered heteroaryl group; R and R or R and R may form together with the corresponding carbon atoms a ring containing -O-CH2-O- or -CH=CH-CH=CH-; R is hydrogen or -C(O)R'; R' is a five or six membered non aromatic heterocyclyl group, five or six membered heteroaryl group or is aryl, which rings may be substituted by the groups, selected from lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, -C(O)H, -C(O)OH or by pyrrolidin-1-yl-methyl; n is 1 to 4; and to their pharmaceutically acceptable salts, wherein the cyclization is carried out by the treatment of a compound of formula with sulphoxide/HBr/solvent to give the desired products of formula (I) for R is hydrogen (formula IA) and for R is -C(O)R' (formula IB).
Abstract:
The invention is concerned with a new scalable process for the preparation of compounds of formula (I) comprising a new process for the preparation of the key intermediate, a dihydropyrrole derivative formula (II) or a salt thereof.
Abstract:
The invention is concerned with a new scalable process for the preparation of compounds of formula (I) comprising a new process for the preparation of the key intermediate, a dihydropyrrole derivative formula (II) or a salt thereof.
Abstract:
The invention provides a process for manufacturing 5-ethyl-4-methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I), or a pharmaceutically acceptable salt thereof, on an industrial scale, Formula (I), comprising a one-pot process for manufacturing 5-ethyl-4-methyl-lH-pyrazole-3- carboxylic acid (1).